ArticleArchives of medical science : AMS2017
The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan.
Article in Archives of medical science : AMS, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Effect of angiotensin receptor neprilysin inhibitors in patients with STEMI: a systematic review and meta-analysis.Future cardiology · 2025Pooled it
- Efficacy and safety of sacubitril/valsartan vs. valsartan in patients with acute myocardial infarction: A meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Review
- What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies.Journal of cardiovascular development and disease · 2022Review
- Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction.Frontiers in cardiovascular medicine · 2022Article
- Molecular mechanisms of sacubitril/valsartan in cardiac remodeling.Frontiers in pharmacology · 2022Review
- Length of stay and readmission in older adults hospitalized for heart failure.Archives of medical science : AMS · 2021Article
- Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel.Frontiers in cell and developmental biology · 2021Article
- Therapeutic effects of higenamine combined with [6]-gingerol on chronic heart failure induced by doxorubicin via ameliorating mitochondrial function.Journal of cellular and molecular medicine · 2020Article
- Natriuretic Peptides in Heart Failure with Preserved Left Ventricular Ejection Fraction: From Molecular Evidences to Clinical Implications.International journal of molecular sciences · 2019Review
- ARNi: A Novel Approach to Counteract Cardiovascular Diseases.International journal of molecular sciences · 2019Review
- The role of B-type natriuretic peptide in diagnosing acute decompensated heart failure in chronic kidney disease patients.Archives of medical science : AMS · 2018Article
- Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy.Therapeutic advances in cardiovascular disease · 2018Review
- Review
- Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.Vascular health and risk management · 2017Review
- Update of treatment of heart failure with reduction of left ventricular ejection fraction.Archives of medical sciences. Atherosclerotic diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is one of the leading causes of morbidity, mortality, and health care expenditures in the US and worldwide. For three decades, the pillars of treatment of HF with reduced ejection fraction (HFrEF) were medications that targeted the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). Prior attempts to augment the natriuretic peptide system (NPS) for the management of HF failed either due to lack of significant clinical benefit or due to the unacceptable side effect profile. This review article will discuss the NPS, the failure of early drugs which targeted the NPS as therapies for HF, and the sequence of events which led to the development of sacubitril plus valsartan (Entresto; LCZ696; Novartis). LCZ696 has been shown to be superior to the standard of care available for treatment of HFrEF in several substantial hard endpoints including heart failure hospitalizations, cardiovascular mortality, and all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.